Key result
Sirolimus-eluting stents and bare-metal stents showed no significant overall differences in markers of platelet activation and coagulation in patients with stable CAD over 6 months.
Why the study?
Does sirolimus-eluting stent implantation affect long-term platelet activation and coagulation markers compared to bare-metal stent implantation in patients with stable coronary artery disease?
RCT (n=47)
randomly allocated
Does sirolimus-eluting stent implantation affect long-term platelet activation and coagulation markers compared to bare-metal stent implantation in patients with stable coronary artery disease?
Sirolimus-eluting stents and bare-metal stents demonstrate similar long-term profiles regarding platelet activation and coagulation markers in stable CAD patients, with transient post-procedural increases resolving by 6 months.
Answers are grounded in this paper and cite their sources.
May guide stent selection independent of these markers in stable CAD; confirms transient activation resolves similarly by 6 months.
BACKGROUND: Platelet activation is crucial in the development of stent thrombosis following percutaneous coronary intervention (PCI). We carried out a long-term assessment of multiple factors implicated in the thrombotic process and monitored markers of platelet activation after the implantation of sirolimus-eluting stents (SES) in patients with stable coronary artery disease (CAD). Additionally, we compared these findings with those after bare-metal stent (BMS) implantation. METHODS: A cohort of 47 consecutive patients, aged <70 years, with severe stenosis (>70% narrowing of the lumen) of one major epicardial coronary artery and stable CAD underwent successful elective PCI. Patients were randomly allocated to SES (n = 25) or BMS (n = 22). Venous blood was obtained 24 hours before and 24 hours, 48 hours, 1 month, and 6 months after PCI for measurements of plasma levels of sP-selectin, von Willebrand Factor (vWF), fibrinogen, d-dimer, sCD40, factor VIII, b-thromboglobulin (b-TG) and platelet factor 4 (PF-4). RESULTS: There were no significant differences between the two groups in levels of fibrinogen or d-dimers in peripheral blood. However, we observed a significant kinetic effect (p<0.001) and stent-effect (p<0.015) on vWF levels and a significant kinetic effect (p = 0.012) on factor VIII, sP-selectin (p = 0.04), b-TG (p<0.001), and PF4 (p = 0.016). A trend towards a significant stent effect on sCD40 was also detected (p = 0.06). CONCLUSIONS: SES and BMS did not show significant differences in relationship to markers of platelet activation and coagulation in patients with stable CAD. Although some markers showed an increase after stent implantation, they returned to the initial levels 6 months later.
No takes yet. Share an insight, caveat, or question.
Marketou et al. (2017) conducted an RCT in stable coronary artery disease (n=47). Sirolimus-eluting stents (SES) vs. Bare-metal stent (BMS) was evaluated on Plasma levels of sP-selectin, von Willebrand Factor (vWF), fibrinogen, d-dimer, sCD40, factor VIII, b-thromboglobulin (b-TG) and platelet factor 4 (PF-4). Sirolimus-eluting stents and bare-metal stents showed no significant overall differences in markers of platelet activation and coagulation in patients with stable CAD over 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: